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while the native tissue was visually and acoustically homogeneous, the
engineered tissue contains structural discontinuities which correlate well
with the acoustic discontinuities.
Fig. 1. Reﬂections from the front and rear faces of native bovine
cartilage (A) or tissue engineered cartilage (B). In contrast to the native
tissue, there are numerous reﬂections in the engineered tissue.
Conclusions: We have previously shown that speed of sound
measurements can be used to estimate actual mechanical properties
of hydrogels and are working to extend these ﬁndings to cartilage.
The present proof of concept work suggests that ultrasound can
also be used to assess, in a non-contact, non-destructive fashion the
internal homogeneity of growing TE cartilage. We thus suggest that
acoustic homogeneity of engineered tissue is a useful predictor of tissue
homogeneity and thus can be used as a further quality control measure.
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ENGINEERING MURINE STEM CELL DERIVED BONE AND CARTILAGE
IN NOVEL BIOMIMETIC BIOREACTOR
P. Lee, D. Rancourt, R. Krawetz. Univ. of Calgary, Calgary, AB, Canada
Purpose: Research in bone and cartilage engineering for regenerative
medicine approaches has expanded over the last decade; however,
few methods have been clinically translated. Partially because most
engineered constructs lack anatomical and mechanical characteristics
of native tissues, and can be resorbed after implantation. In this study,
we have derived an engineered bone and cartilage construct (EBCC)
that is collagen based; within a novel biomimetic bioreactor. Previous
results from our lab demonstrated collagen 1 and chondroitin sulphate
to be potent inducers for osteogenesis and chondrogenesis respectively.
However, prolonged maintenance cell viability and application of
mechanical stimulants remains a hurdle in static tissue culture setting.
Hence, a novel bioreactor system capable of emulating physiological
environment speciﬁc for bone and cartilage development was designed;
to enhance potential of the EBCC to possess both anatomical and
mechanical resemblance to tissue in physiology.
Methods: A perfusion bioreactor was designed to provide continual
ﬂow of media to the EBCC at constant ﬂow rate. The design allows
alternation of media compositions in real-time, based on the needs
of the EBCC at each stage of differentiation with minimal disruptions.
An isolated polymerized collagen 1 platform was fabricated within
the bioreactor to support embryonic stem cells (ESC) differentiation.
Nutrients and oxygen gradients developed within the bioreactor are
based on the design of bioreactor and seeding density of ESCs. This
gradient is exploited (with media supplementation) to promote both
osteogenesis and chondrogenesis at different parts of the platform;
resulting in EBCC formation. Furthermore, the materials used to assemble
the bioreactor are amenable to direct mechanical stimulation (bending
and compression) and is applied to the developing EBCC to enhance
differentiation.
Results: Cells in EBCC remained viable for at least 45 days post
inoculation, with extensive cellular remodelling observed. A construct
with ﬁrm structural features was developed. Quantitative PCR (qPCR)
analyses demonstrated signiﬁcant decrease in pluripotent marker, OCT-4,
after 30 days, with coinciding increases in osteogenic and chondrogenic
markers.
Conclusions: This novel bioreactor promotes long term cultivation and
differentiation of the EBCC. Using the cast and mould concept, we
had established an EBCC with speciﬁc shape, that retains mechanical
properties after removal from the bioreactor. In future experiments we
will be applying various mechanical stimulants on the EBCC to drive
further maturation and transplant the construct into critical size skeletal
defects. The EBCC principle, once validated in vitro and in vivo holds
promises as an alternative approach for producing custom implants that
can contain both bone and cartilage components.
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Purpose: Mesenchymal stem cells (MSCs) are promising candidates
for cell therapeutic application in osteoarthritis (OA) and rheumatoid
arthritis (RA). The catabolic environment in joints of OA and RA patients
results in progressive joint damage. MSCs can have anti-catabolic or
anti-inﬂammatory effects by secreting anti-inﬂammatory cytokines and
growth factors. In order to become immunosuppressive MSCs need to be
triggered by for instance pro-inﬂammatory cytokines. We hypothesized
that synovial ﬂuids inﬂuences the immunomodulatory effects of MSCs
and investigated this in vitro by analyzing the gene expression of
immunomodulatory factors.
Methods: Human bone marrow derived MSCs were cultured in
monolayer in serum-free medium with 1% ITS with or without 20%
synovial ﬂuid for 48 hours. Synovial ﬂuid of six OA donors, six RA
donors and three healthy donors were used in triplicate cultures. Gene
expression of immunoregulatory cytokines IL-6, HGF, TNFa, TGFb1 and
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indoleamine 2,3-dioxygenase (IDO) were analysed and related to the
Best Keeper Index with GAPDH, HPRT and UBC as house keeping genes.
Statistical analysis was performed using a mixed model ANOVA, in which
treatment was considered a ﬁxed factor and the different synovial ﬂuid
donors a random factor. A P-value of <0.05 was considered statistically
signiﬁcant.
Results: Synovial ﬂuid in general upregulated the expression of IL-6
(2.7±1.6 fold, p = 0.045), IDO (4.1±2.7 fold, p = 0.013) and TNFa (2.9±2.0
fold, p = 0.046) in MSCs, while HGF and TGFb1 gene expressions were
not affected (Figure 1).
Synovial ﬂuid of OA patients induced a 1.69±1.47 fold (p = 0.031) higher
expression of IDO than synovial ﬂuid of healthy donors. No further
differences between synovial ﬂuid of OA and RA patients compared to
healthy donors on the gene expression of MSCs were found.
Conclusions: Synovial ﬂuid inﬂuences the expression of genes involved
in immunomodulation in MSCs. The upregulated expression of IL-6, TNFa
and IDO could indicate a response of the MSCs to inﬂuence the balance
between the catabolic and anabolic state. IDO is an immunomodulatory
enzyme that catalyzes the ﬁrst and rate-limiting step in the kynurenine
pathway thereby inhibiting T-cell proliferation and stimulating the
differentiation of regulatory T-cells. The upregulated expression of IDO
by OA versus healthy synovial ﬂuid indicates that MSCs can be triggered
to exert anti-inﬂammatory effects in a diseased joint.
These results suggest a possible anti-inﬂammatory effect MSCs could
have intra-articular in a diseased joint and stimulate further study of
MSCs as treatment for OA and RA.
Fig. 1. Effect of synovial ﬂuid on gene expression of immunomodulatory
factors by MSCs.
475
CHONDROGENIC DIFFERENTIATION OF BONE MARROW
MESENCHYMAL STEM CELLS (BM-MSCS) GROWN ON COLLAGEN
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Purpose: To study the chondrogenic potential of human bone marrow
mesenchymal stem cells (hBM-MSCs) grown on a mixture of type I and
II collagen supports.
Methods: hBM-MSCs were isolated from human BM stroma and were
expanded in monolayer cultures. hBM-MSCs were characterized by ﬂow
cytometry using hematopoietic and MSC markers. At the 3–4th passage,
hBM-MSCs were cultured on 1x1 cm2type I/II collagen porous supports,
pre-treated or not with PTHrP (1–36) or PTHrP (107–139) (100 nM) for 1.5
h. The cell density over the support was 50.000 cells/cm2. We performed
18 groups: 9 in normoxia (humidiﬁed atmosphere with 5% CO2) and
the other 9 in hypoxia conditions (obtained with GasPak™ EZ Anaerobe
Pouch System, BD Diagnostics). Within each group, 5 replicas were done.
The study period was 14 days for the groups tested in hypoxia and
21 days for those in normoxia. hBM-MSCs were cultured in chondrogenic
differentiation medium (Lonza, Group Ltd, Switzerland) or DMEM with
20% FBS. Control groups were mature human chondrocytes grown in
DMEM with 10% FBS. Chondrogenic differentiation was conﬁrmed by
histochemical and immunohistochemical analysis
Results: By means of hematoxylin-eosin stainings it was found that both
hBM-MSCs and chondrocytes were able to grow on collagen type I/II
supports, not only in the presence (C-terminal and N-terninal PTHrP)
but also in the absence of PTHrP. However cultures without PTHrP
showed a lower rate of cell proliferation. Moreover, in some study
groups it was observed the production of an extracellular matrix. At
the same time that hBM-MSCs proliferated over the support, they were
able to degrade the biomaterial although it is important to note that
larger collagen ﬁbers are more difﬁcult to be degraded by the cells.
It was observed that cells were interconnected with each other and
also with the biomaterial, so that they were radiating from the center
toward the edge of the support. The hBM-MSCs grown in chondrogenic
medium were able to differentiate into cells that showed characteristics
similar to chondrocytes. To demonstrate the chondrogenic differentiation
some immunostainings were performed in order to detect the presence
of different characteristic components of the articular cartilage. As it
is shown in Figure 1, the cells showed positive immunostaining for
collagen II and one of the most abundant proteoglycan of cartilage
(aggrecan). Moreover, positivity for types I and X collagens and MMP13
was also observed. In the case of immunohistochemistry for PCNA, a
marker of proliferation, it was observed that cells despite being in
culture over the biomaterial for 14 and 21 days, they proliferated without
showing any sign of apoptosis or senescence.
Conclusions: Our data demonstrate that type I/II collagen scaffolds are
optimal for hBM-MSCs and chondrocyte growth. Moreover, both N- and
C-terminal fragments of PTHrP improve the capacity of hBM-MSCs to
differentiate into chondrocyte-like cells.
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Fig. 1. Immunohistochemistry (A) and semi-quantitative (B) analysis of
hBM-MSCs grown on type I/II collagen supports in normoxia conditions
and in chondrogenic medium. Col-I, -II, -X: collagen types I, II and X.
PCNA: proliferating cell nuclear antigen. MMP-13: metalloproteinase 13.
Image magniﬁcation 10×.
